PET/CT without capacity limitations: A Danish experience from a European perspective

European Radiology

Volumn 21, Issue 6, 2011, Pages 1277-1285

  Høilund Carlsen, Poul Flemming ^a   Gerke, Oke ^a   Vilstrup, Mie Holm ^a   Nielsen, Anne Lerberg ^a   Thomassen, Anders ^a   Hess, Søren ^a   Høilund Carlsen, Mette ^a   Vach, Werner ^b   Petersen, Henrik ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Clinical impact; Indications; PET CT; Radionuclide imaging; Referral pattern

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHILD; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GYNECOLOGY; HEMATOLOGY; HUMAN; INFANT; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; ONCOLOGY; PATIENT CARE; PATIENT REFERRAL; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIODIAGNOSIS; SCHOOL CHILD; SURGERY; TREATMENT RESPONSE;

DENMARK; EUROPE; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; UTILIZATION REVIEW;

EID: 79959296801     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-010-2025-y     Document Type: Article

References (29)

1. Centers for Medicare and Medicaid Services (2002-2009) NCD for Positron Emission Tomography (PET) Scans (220.6) [Medical Coverage Database on the Internet]. Centers for Medicare and Medicaid Services, Baltimore. Available via http://www.cms.hhs.gov/mcd/viewncd.asp?ncd-id=220.6&ncd-version= 4&basket=ncd%3A220%2E6%3A4%3APositron+Emission+Tomography+% 28PET%29+Scans. Accessed 21 July 2010
2. Hillner BE, Liu D, Coleman RE, Shields AF et al (2007) The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med 48:1901-1098
3. Podoloff DA, Advani RH, Allred C et al (2007) NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Cancer Netw 5(Suppl 1):S1-S22
4. Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11S-S20
5. Boellaard R, O'Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181-200
6. Allen-Auerbach M, Weber WA (2009) Measuring response with FDG-PET: methodological aspects. Oncologist 14:369-377
7. Weber WA (2009) Assessing tumor response to therapy. J Nucl Med 50:1S-10S
8. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50:122S-150S
9. Långström B, Bergström M, Antoni G, Engler E (2001) Uppsala University PET Centre 1989-2001. Uppsala University PET Centre, Uppsala
10. About Turku PET Centre-History. Turku PET Centre, Turku. Available via http://pet.utu.fi/history.html. Accessed 21 July 2010
11. Rodell A (2003) On the trail of inner life. PET in Århus 1993-2003. Århus PET Center, Århus
12. Danish Institute of Radiation Protection (2009) [The use of radiopharmaceutical in nuclear medicine examinations and treatments in Denmark 2008]. Danish Institute of Radiation Protection, Danish National Board of Health, Copenhagen. Available via http://www.sst.dk/publ/Publ2009/SIS/Nuklear- medicin/Nuklearmedicinsk-sammentaelling-2008.pdf. Accessed 21 July 2010
13. European Association of Nuclear Medicine (2006) Status of nuclear medicine in Europe-2006. EANM'06 statistics survey. EANM, Vienna
14. European Association of Nuclear Medicine (2007) Status of nuclear medicine in Europe-2007. EANM'07 statistics survey. EANM, Vienna
15. European Association of Nuclear Medicine (2009) Status of nuclear medicine in Europe-2009. EANM'09 statistics survey. EANM, Vienna
16. World Health Organisation (2007) International Statistical Classification of Diseases and Related Health Problems 10th Revision. Version for 2007. World Heath Organisation and German Institute of Medical Documentation and Information. Available from. http://apps.who.int/classifications/apps/icd/ icd10online/. Accessed 21 July 2010
17. Tucker R, Coel M, Ko J, Morris P, Druger G, McGuigan P (2001) Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center. J Clin Oncol 19:2504-2508 (Pubitemid 32391221)
18. Gutte H, Højgaard L, Kjær A (2005) Early clinical experience and impact of 18F-FDG PET. Nucl Med Commun 16:989-994 (Pubitemid 41527289)
19. Gopalan D, Griffiths D, Townsend C, Prvulovich E, Bomanji J, Costa DC, Ell PJ (2002) Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrer's perspective. Nucl Med Commun 23:1041-1046 (Pubitemid 35398976)
20. Hillner BE, Tunuguntla R, Fratkin M (2004) Clinical decision associated with positron emission tomography in prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol 22:4147-4156 (Pubitemid 41185185)
21. Lau WF, Binns DS, Ware RE, Ramdave S, Cachin F, Pitman AG, Hicks RJ (2005) Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia. Med J Aust 182:172-176 (Pubitemid 40298184)
22. Hillner BE, Siegel BA, Liu D et al (2008) Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET registry. J Clin Oncol 26:2155-2161
23. Hillner BE, Siegel BA, Shields AF et al (2009) The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer 115:410-418, Erratum in: Cancer 115:1133
24. Facey K, Bradbury I, Laking G, Payne E (2007) Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol 11:iii-iv, xi-267
25. Långström B, Grahnen A, Honoré PH et al (2009) The risk of exaggerated risk aversion - a life and death struggle for molecular imaging. Eur J Nucl Med Mol Imaging 36:1693-1694
26. Danish National Board of Health (2006) PET (Positron emission tomography). Recommendations for the elaboration of PET and FDG production]. Danish National Board of Health, Copenhagen. Available via http://www.sst.dk/ publ/Publ2006/PLAN/PET/PET-FDG.pdf. Accessed 21 July 2010
27. Market Research.com (2009) Europe nuclear imaging equipment: market analysis and opportunity assessment. Available via http://www. researchandmarkets.com/reports/1195848. Accessed 21 July 2010
28. European Association of Nuclear Medicine (2008) Official EANM Position: The medical use of radiopharmaceuticals up to 2025. An exploration of the future medical use of radio-isotopes. A report written and translated by Technopolis Group, commissioned by the Dutch Ministry of Housing, Spatial Planning and the Environment (VROM), and supported by the Dutch Society of Nuclear Medicine (NVNG) under the lead of Dr. J.F. Verzijlbergen. Available via https://www.eanm.org/news/official-eanm-position.php?navId=658. Accessed 21 July 2010
29. Cuocolo A, Bretnach É (2010) Multimodality imaging in Europe: a survey by the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR). Eur J Nucl Med Mol Imaging 37:163-167